Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. (linkinghub.elsevier.com)

Authors: Clowse MEB … Stach C Journal: The Lancet Published: 2026-06-06 DOI: https://doi.org/10.1016/S0140-6736(26)00691-4